Logo image of HCWB

HCW BIOLOGICS INC (HCWB) Stock Fundamental Analysis

NASDAQ:HCWB - Nasdaq - US40423R2040 - Common Stock - Currency: USD

5.22  -0.27 (-4.92%)

Premarket: 5.22 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HCWB. HCWB was compared to 559 industry peers in the Biotechnology industry. Both the profitability and financial health of HCWB have multiple concerns. HCWB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

HCWB had negative earnings in the past year.
HCWB had a negative operating cash flow in the past year.
In the past 5 years HCWB always reported negative net income.
In the past 5 years HCWB always reported negative operating cash flow.
HCWB Yearly Net Income VS EBIT VS OCF VS FCFHCWB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

HCWB's Return On Assets of -94.12% is on the low side compared to the rest of the industry. HCWB is outperformed by 74.42% of its industry peers.
Industry RankSector Rank
ROA -94.12%
ROE N/A
ROIC N/A
ROA(3y)-72.68%
ROA(5y)-57.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HCWB Yearly ROA, ROE, ROICHCWB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

HCWB has a Gross Margin of 24.46%. This is in the better half of the industry: HCWB outperforms 73.52% of its industry peers.
HCWB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HCWB Yearly Profit, Operating, Gross MarginsHCWB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HCWB has been increased compared to 1 year ago.
Compared to 5 years ago, HCWB has more shares outstanding
Compared to 1 year ago, HCWB has a worse debt to assets ratio.
HCWB Yearly Shares OutstandingHCWB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
HCWB Yearly Total Debt VS Total AssetsHCWB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -9.40, we must say that HCWB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.40, HCWB is doing worse than 72.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.4
ROIC/WACCN/A
WACC9.06%
HCWB Yearly LT Debt VS Equity VS FCFHCWB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

HCWB has a Current Ratio of 0.07. This is a bad value and indicates that HCWB is not financially healthy enough and could expect problems in meeting its short term obligations.
HCWB's Current ratio of 0.07 is on the low side compared to the rest of the industry. HCWB is outperformed by 98.03% of its industry peers.
HCWB has a Quick Ratio of 0.07. This is a bad value and indicates that HCWB is not financially healthy enough and could expect problems in meeting its short term obligations.
HCWB has a Quick ratio of 0.07. This is amonst the worse of the industry: HCWB underperforms 97.85% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
HCWB Yearly Current Assets VS Current LiabilitesHCWB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.61% over the past year.
HCWB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.04%.
EPS 1Y (TTM)16.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.47%
Revenue 1Y (TTM)-63.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.11%

3.2 Future

Based on estimates for the next years, HCWB will show a decrease in Earnings Per Share. The EPS will decrease by -1.16% on average per year.
HCWB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 109.56% yearly.
EPS Next Y3.51%
EPS Next 2Y2.6%
EPS Next 3Y-1.16%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y109.56%

3.3 Evolution

HCWB Yearly Revenue VS EstimatesHCWB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2028 2029 2030 200M 400M 600M
HCWB Yearly EPS VS EstimatesHCWB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HCWB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HCWB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HCWB Price Earnings VS Forward Price EarningsHCWB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCWB Per share dataHCWB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.6%
EPS Next 3Y-1.16%

More info and screens

0

5. Dividend

5.1 Amount

HCWB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HCW BIOLOGICS INC

NASDAQ:HCWB (6/11/2025, 8:00:01 PM)

Premarket: 5.22 0 (0%)

5.22

-0.27 (-4.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/dmh
Earnings (Next)N/A N/A
Inst Owners7.02%
Inst Owner Change-63.07%
Ins Owners40.57%
Ins Owner Change18.01%
Market Cap9.92M
Analysts82.86
Price Target35.7 (583.91%)
Short Float %21.85%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-70.83%
PT rev (3m)1066.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-3900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-25.15
EYN/A
EPS(NY)-22.03
Fwd EYN/A
FCF(TTM)-7.39
FCFYN/A
OCF(TTM)-7.32
OCFYN/A
SpS0.76
BVpS-4.74
TBVpS-4.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.46%
FCFM N/A
ROA(3y)-72.68%
ROA(5y)-57.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.56%
Cap/Sales 8.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -9.4
F-Score1
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)664.56%
Cap/Depr(5y)406.92%
Cap/Sales(3y)127.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.47%
EPS Next Y3.51%
EPS Next 2Y2.6%
EPS Next 3Y-1.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-63.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.11%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y109.56%
EBIT growth 1Y17.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.82%
OCF growth 3YN/A
OCF growth 5YN/A